Phaseline

Companies › Shenzhen Hemogen

Shenzhen Hemogen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
β-globin restored autologous hematopoietic stem cells (HGI-001)
Lentiviral-transduced CD34+ HSCs with LentiHBBT87Q delivering functional β-globin gene
HBBPhase 1Β-thalassemiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06655662β-globin restored autologous hematopoietic stem cells (HGI-001)Phase 1Β-thalassemiaHematologyDec 2026

Targets

HBB (1)

Companies with the same targets

Genetix Biotherapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.